Specification
| Target | C1s |
| Clone | Sutimlimab |
| Isotype | Human IgG4(S228P/L235E)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | Anti-HEL Human IgG4 (S228P/L235E)-Kappa Isotype control |
| Recommended Dilution Buffer | PBS, pH 7.13 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway.1 It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |